Last Updated: March 6, 2024

Kava (Piper methysticum) is a plant that has had many traditional uses throughout history, especially among South Pacific Islanders. It is best known for anxiety reduction but comes with some serious safety concerns when used in excess.

Kava is most often used for.

Don't miss out on the latest research

1.^Ballotin VR, Bigarella LG, Brandão ABM, Balbinot RA, Balbinot SS, Soldera JHerb-induced liver injury: Systematic review and meta-analysis.World J Clin Cases.(2021-Jul-16)
2.^Becker MW, Lourençone EMS, De Mello AF, Branco A, Filho EMR, Blatt CR, Mallmann CA, Schneider M, Caregnato RCA, Blatt CRLiver transplantation and the use of KAVA: Case report.Phytomedicine.(2019-Mar-15)
3.^Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PWFatal fulminant hepatic failure induced by a natural therapy containing kava.Med J Aust.(2003-May-05)
4.^Brauer RB, Stangl M, Stewart JR, Pfab R, Becker KAcute liver failure after administration of herbal tranquilizer kava-kava (Piper methysticum).J Clin Psychiatry.(2003-Feb)
5.^Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah AIn vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes.Clin Pharmacol Ther.(2005-May)
6.^Sarris J, Stough C, Teschke R, Wahid ZT, Bousman CA, Murray G, Savage KM, Mouatt P, Ng C, Schweitzer IKava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects.Phytother Res.(2013-Nov)
7.^Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong YSupplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo.Clin Pharmacol Ther.(2008-Jan)
9.^Cagnacci A, Arangino S, Renzi A, Zanni AL, Malmusi S, Volpe AKava-Kava administration reduces anxiety in perimenopausal women.Maturitas.(2003-Feb-25)
14.^Pittler MH, Ernst EKava extract for treating anxietyCochrane Database Syst Rev.(2003)
15.^Sarris J, Stough C, Bousman CA, Wahid ZT, Murray G, Teschke R, Savage KM, Dowell A, Ng C, Schweitzer IKava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study.J Clin Psychopharmacol.(2013-Oct)
16.^Sarris J, Laporte E, Scholey A, King R, Pipingas A, Schweitzer I, Stough CDoes a medicinal dose of kava impair driving? A randomized, placebo-controlled, double-blind study.Traffic Inj Prev.(2013)
17.^Sarris J, Byrne GJ, Bousman CA, Cribb L, Savage KM, Holmes O, Murphy J, Macdonald P, Short A, Nazareth S, Jennings E, Thomas SR, Ogden E, Chamoli S, Scholey A, Stough CKava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled studyAust N Z J Psychiatry.(2019 Dec 8)
21.^Singh YNKava: an overview.J Ethnopharmacol.(1992-Aug)
22.^D D Jamieson, P H DuffieldPositive interaction of ethanol and kava resin in miceClin Exp Pharmacol Physiol.(1990 Jul)
23.^Cairney S, Clough AR, Maruff P, Collie A, Currie BJ, Currie JSaccade and cognitive function in chronic kava users.Neuropsychopharmacology.(2003-Feb)
24.^Cairney S, Maruff P, Clough AR, Collie A, Currie J, Currie BJSaccade and cognitive impairment associated with kava intoxication.Hum Psychopharmacol.(2003-Oct)